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Objective: Smoking represents a major public health problem among patients with
schizophrenia. To this end, some studies have investigated the efficacy of varenicline
for facilitating smoking cessation in schizophrenia patients. The present review seeks to
synthesize the results of these studies as well as document the reported side effects of
using this medication.
Methods: An electronic search was performed using five major databases: PubMed,
Scopus, EMBASE, Web of Science, and Cochrane Library. Included in the current
analysis were randomized clinical trials (RCTs) that have investigated the effect of
varenicline in promoting smoking cessation in patients with schizophrenia. Risk of
bias among included RCTs was assessed using the Cochrane Collaboration’s quality
assessment tool.
Results: Among the 828 screened articles, only four RCTs, which involved 239
participants, were eligible for meta-analysis. In patients with schizophrenia, varenicline
treatment when compared to placebo significantly reduced the number of cigarettes
consumed per day [SMD (95% CI) = 0.89(0.57–1.22)] and expired carbon monoxide
levels [SMD (95% CI) = 0.50 (0.06–0.94)] respectively.
Conclusion: Despite a limited number of studies included in the meta-analysis, our
results suggest that varenicline is an effective and safe drug to assist smoking cessation
in patients with schizophrenia. Future large-scale well-designed RCTs are required to
validate these findings.
Keywords: schizophrenia, cigarettes, nicotine addiction, smoking cessation, varenicline
INTRODUCTION
Smoking among patients with schizophrenia continues to be a major public health problem. There
is a strong association between schizophrenia and smoking behaviors, with prevalence rates ranging
from 70 to 90%; as a comparison, smoking rates of the general population in the United States
stands at∼30% (1, 2). Also, compared to smokers in the general population, schizophrenic smokers
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consume more cigarettes per day (3). Schizophrenic patients
usually smoke heavily, extract higher levels of nicotine, and have
higher nicotine dependence scores than smokers who do not have
schizophrenia (3–7).
Several hypotheses have been proposed to explain the high
rates of smoking in this patient population. The most popular
hypothesis, which is known as “self-medication hypothesis
(SMH)”, argues that these patients smoke in order to manage
their negative symptoms by regulating and compensating for
the underlying neurobiological deficits associated with the
disorder such as cognitive deficits. Smoking may transiently
alleviate negative symptoms in schizophrenic patients by
increasing dopaminergic and glutamatergic neurotransmission
in the prefrontal cortex. Also, nicotine improves some cognitive
deficits common in patients with schizophrenia, such as sensory
gating deficits, abnormalities in smooth-pursuit eye movements,
selective attention, visuospatial working memory limits, and
attention deficits; also, high-dose nicotine increases abnormality
in P450 inhibition (8). Contrary to these temporary benefits,
there is abundant evidence that clearly shows that smoking is
harmful because it increases the risk of contracting numerous
medical illnesses such as lung cancer and other smoking-related
diseases. Mortality rates also reflect this trend; patients with
schizophrenia who smoke face mortality rates from smoking-
related health issues that are two to six times higher than
other smokers. They confront increased risks of cardiovascular
disease, respiratory disease, and cancer (9). The increased
mortality risks that result from smoking exacerbates already
high mortality risk schizophrenic patients. This higher mortality
risk results in about a 20–25% reduction in average lifespan
for people with schizophrenia (4). Schizophrenic patients are at
higher risk of fatal cardiovascular disease and other causes of
premature death such as obesity, sedentary lifestyle, diabetes,
hypertension, or hypertriglyceridemia (10). The risk of HIV
(human immunodeficiency virus) and infectious hepatitis is also
high in this population. The suicide rate is 10% compared to
1% in the general population; the most likely explanations for
this higher risk of death include less access to medical care,
engagement in high-risk behaviors, and poorer compliance with
treatment (11). Concerning morbidity in particular, second-
generation antipsychotics are more likely to cause weight
gain and metabolic syndrome compared to first-generation
antipsychotics, and these side effects are associated with a
two-to-threefold increase in cardiovascular mortality and a
twofold increase in mortality in general (12). The increased
risk of mortality in schizophrenics affects men and women
equally, although there are sex differences in the epidemiological
features of schizophrenia (12). Therefore, the added health
risks associated with smoking are particularly dangerous to this
population and must be addressed.
Clinicians often do not address nicotine addiction in the
schizophrenic population because of the popular beliefs that
treatment could worsen the patient’s illness or that the patient
is not willing to quit (3). However, numerous studies have
demonstrated that stable patients with schizophrenia can tolerate
cessation attempts without an overall worsening of their illness
and can have moderate short-term success in smoking cessation
(2–4, 13–22). Once these patients demonstrate a willingness
to quit smoking, they can try numerous therapeutic options
that have proven to be beneficial. In 2006, the FDA approved
varenicline, a partial agonist of α4β2 acetylcholine receptor
and a full α7 nicotinic acetylcholine receptor agonist for
smoking cessation. This drug ameliorates withdrawal symptoms,
specifically reducing cravings, and it works as a positive
reinforcement for the cessation of smoking. However, there have
been some reports of side effects that include the exacerbation of
psychiatric symptoms such as depression, aggression, psychosis,
and suicidal thoughts and behaviors (23–28). As a result
of these sometimes dangerous side effects, the FDA issued
a black box warning in 2009 (29). However, several recent
studies have provided evidence regarding its safety in facilitating
smoking cessation in patients with schizophrenia (9, 15, 30–33).
Numerous published clinical trials have found varenicline to be
effective, safe, and well tolerated in terms of neuropsychiatric
adverse events, with a common possible side effect of mild
to moderate nausea similar to that experienced by the general
populations (3, 4, 34–39). A recently published meta-analysis
TABLE 1 | List of studies considered at the final stage of study selection.
Study Included? Reason for exclusion
Dutra et al. (42) No No control group
Williams et al. (33) Yes
Pachas et al. (9) No No control group
Fatemi et al. (45)
(clinicaltrial.gov)
No No baseline measures with which to
assess outcomes
Weiner et al. (19) Yes
Jeon et al. (43) Yes
Coles et al. (32)
(poster abstract)
No No relevant data to extract.
Conference poster; only abstract
available
Hong et al. (46) Yes
FIGURE 1 | PRISMA flow diagram of studies’ selection and screening.
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of this subject concluded that varenicline is not superior to
placebo in smoking cessation (40). However, the results of this
metanalysis run counter to numerous studies that have found
varenicline to be an effective, safe, and well-tolerated treatment
for smoking cessation in schizophrenic patients (3, 33, 41, 42).
Because of these positive findings as well as a new study on this
topic (43), we sought to synthesize previous findings and examine
the overall effect of varenicline on smoking cessation among
patients with schizophrenia.
METHODS
Search Strategy and Selection Criteria
The Recommendations from the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) Statement
were adopted to conduct this systematic review and meta-
analysis (44). Five databases were systematically searched
including PubMed, Scopus, EMBASE, Web of Science and
Cochrane’s library for articles published up until July 2018.
We performed an electronic search on this topic with no
restrictions regarding language or publication date. The
Boolean search we conducted utilized the following keyword
combinations: varenicline AND [(schizophrenia spectrum
disorder) OR schizophrenia OR (schizoaffective disorder) OR
(schizophreniform disorder) OR (delusional disorder)], the
strategy was adjusted to suit each of the chosen search engines
and databases. We further considered performing a manual
search in reference lists of relevant studies. Once we completed
the search, we elected to include only RCTs that investigated the
effects of varenicline on either smoking cessation or smoking
reduction in patients with schizophrenia, schizophreniform,
schizoaffective, or delusional disorder. We excluded reviews, case
series, case reports, comments, opinion, unpublished studies,
conference posters, and abstracts only. We also excluded studies
with overlapped data or data that could not be extracted. Three
authors (SA, PVK, and RA) blindly screened all articles obtained
through the search, based on titles and abstracts, to identify
relevant articles for full-text consideration. Discrepancies were
resolved by discussion, and consensus was achieved. Table 1
shows the list of studies considered in the final stage of selection,
the decision about whether or not to include each relevant study,
and the reasons for excluding the articles which were not chosen.
Data Extraction
Data were extracted by three blinded authors in order to preserve
precision, using a template in Microsoft Excel to extract the
needed data. The data that was extracted included sample size,
age of subject, sex of subject, follow-up period, and drug dosage.
Additionally, data for tested outcomes, the number of cigarettes
FIGURE 2 | Summary of risk of bias assessment according to Cochrane
collaboration tool.
TABLE 2 | Characteristics of included studies.
References DSM-IV
diagnosis
Treatment
duration
in weeks
Dose (mg) Sample size Age mean (SD) Male (%)
Baseline Follow-up
Varenicline Placebo Varenicline Placebo Varenicline Placebo Varenicline Placebo
Williams et al. (33) SCZ/SCA 12 0.5 × 3days, 1 × 4days,
2/day thereafter
84 43 61 37 40.2 (11.9) 43 (10.2) 77.4 76.7
Jeon et al. (43) SCZ 8 0.5 × 3days, 1 × 4days,
2/day thereafter
30 30 23 22 41.1 (8.9) 41.5 (8.8) 86.7 96.7
Hong et al. (46) SCZ/SCA 8 0.5 × 1week, 1 × 7week 20 23 19 21 43 (11) 41.5 (11.4) 65 60.9
Weiner et al. (19) SCZ/SCA 12 1/day 4 5 4 4 ND ND ND ND
SD, standard deviation; SCZ, schizophrenia; SCA, schizoaffective; d, days.
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smoked per day, expired carbon monoxide, and abstinence from
smoking behavior were extracted and meta-analyzed.
Statistical Methods
For dichotomous outcomes which are determined only at post-
treatment, (such as the number of participants who remained
abstinent), the log Odds Ratios (OR) and their respective
sampling variances were calculated using the escalc function in
the meta for package (47) in R. As for continuous outcomes
studied both at baseline and post-treatment, the raw score, single
group, pretest-posttest standardized mean difference (SMD) for
both the treatment and placebo groups were computed separately
(48). Their respective sampling variances were computed using
formula A1 in (48). After this computation was complete, the
placebo group’s SMD was subtracted from that of the treatment
group to obtain the overall SMD for a researched outcome
in the study. The sampling variances of the treatment and
placebo subgroups were then added together to obtain the overall
sampling variance for that outcome in the study (48).
These SMDs were then pooled and meta-analyzed using
random effects models (REM) to allow the effect sizes to vary
across studies. The direction of the effect sizes was coded in
such a way that larger positive effect sizes corresponded to
larger positive differences (i.e., treatment–placebo) in raw scores.
Heterogeneity was measured using the Q statistic; a significant
Q statistic suggests that the variability among the effect sizes is
larger than what is expected from subject sampling error alone.
Follow-up leave-one-out analyses were carried out to assess the
robustness of the results. These analyses were performed using
the metafor package (47) in R 3.4.0.
Quality Assessment
The included studies were independently assessed using
Cochrane collaboration’s tool for assessing risk of bias (49). This
tool is a two-part tool that addresses seven specific domains,
including sequence generation, allocation concealment, blinding
of participants, and personnel, blinding of outcome assessment,
incomplete outcome data, selective outcome reporting, and other
sources of bias. The judgment of each reviewer of each domain
was categorized as “low risk,” “high risk,” or “unclear risk” of
bias. Any disagreement was resolved by discussions between
reviewers until a consensus was reached.
RESULTS
Search Results
The literature search yielded 822 articles. Five RCTs investigated
the efficacy of varenicline in different clinical conditions and thus
did not fulfill the core requirements of this meta-analysis. We
summarize their interventions and the reasons for exclusion of
these studies in Table 1 (9, 32, 42, 45). The flowchart of studies’
selection and screening is presented in Figure 1.
Baseline Characteristics
Our four included RCTs were comprised of 239 participants at
baseline; however, only 191 completed the study and follow-up.
The DSM-IV confirmed only schizophrenia in only one study
(43), while schizophrenia or schizoaffective disorder was present
in the participants in the remaining studies (19, 33, 46). The
participants’ mean age ranged from 40 to 43, andmost of patients
were male. In one of the studies, researchers did not indicate
the age or gender of included participants (19). The treatment
duration was 12 weeks in two studies (19, 33) and only 8 weeks in
TABLE 3 | Summary of leave-one-out analysis.
Study removed SMD 95% CI Q
Williams et al. (33) 0.71** 0.26–1.16 <0.001
Jeon et al. (43) 0.97*** 0.59–1.36 0.79
Hong et al. (46) 0.94*** 0.57–1.31 1.01
SMD, standardized mean difference; CI, confidence intervals; **p < 0.01; ***p < 0.001.
FIGURE 3 | Forest plot meta-analysis of three RCTs illustrating impact of varenicline compared to placebo on cigarette consumption in schizophrenia patients. SMD,
standard mean difference; CI, confidence interval; RE, random effect.
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the two remaining (43, 46). The characteristics of the studies are
detailed in Table 2.
Risk of Bias Among Included RCTs
The random sequence generation presented an unclear risk of
bias among the four included RCTs. Performance, detection,
attrition, and reporting bias were low in all studies. Regarding
allocation concealment, there was an unclear risk of bias in two
studies (19, 46) while there was only a low risk in the remaining
two (33, 43). The risk of bias in the studies is characterized in
Figure 2.
Outcomes
Impact of Varenicline on the Cigarette Consumption
in Schizophrenia Patients
Pooling together the three studies that evaluated the impact
of varenicline on the number of cigarettes consumed per
day, schizophrenic smokers who were given varenicline (N
= 134) had significantly reduced the number of cigarettes
consumed per day, when compared to those given a placebo
(N = 94) (Figure 3). The adverse events among included
RCTs are shown in Table 4. The Q statistic did not suggest
significant heterogeneity in the random effects model (Table 5).
Additionally, the leave-one-out analysis suggested that the
obtained estimate was generally robust and that removal of any of
the three studies did not alter the statistical significance (Table 3).
Impact of Varenicline on the Expired Carbon
Monoxide in Schizophrenia Patients
Regarding levels of carbon monoxide, only two studies evaluated
the impact of varenicline on the expired carbon monoxide
levels before and after treatment (43, 46). Varenicline treatment
(N = 49), compared to placebo (N = 51) significantly reduced
the expired carbon monoxide levels in schizophrenia patients
(Figure 4). Similarly, the Q statistic did not indicate significant
heterogeneity in the random effects model (Table 5).
Impact of Varenicline on the Abstaining From
Smoking Behavior in Schizophrenia Patients
Two studies have assessed the impact of varenicline on abstinence
rates before and after treatment (19, 33). Again, varenicline-
treated schizophrenic patients (N = 87), relative to placebo
group (N = 47), had significantly higher rates of abstaining
from smoking behavior (Figure 5). The Q statistic did not
indicate significant heterogeneity in the random effects model
(Table 5).
Adverse Events of Varenicline Compared to Placebo
in Schizophrenic Patients
The side effects reported in the included RCTs included
gastrointestinal and psychiatric symptoms, as well as headache
and fatigue. Nausea and insomnia were reported in three RCTs
(19, 33, 46), while vomiting, abdominal pain, abnormal dreams,
FIGURE 5 | Forest plot meta-analysis of two RCTs for the impact of varenicline
on abstaining from smoking behavior in schizophrenia patients. CI, confidence
interval; RE, random effect.
FIGURE 4 | Forest plot meta-analysis of two RCTs for the effect of varenicline compared to placebo on the expired carbon monoxide in schizophrenia patients. SMD,
standard mean difference; CI, confidence interval; RE, random effect.
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anxiety, headache, and fatigue were reported in two studies
(33, 46). In only one study did some patients experience diarrhea
and depression (33). Detailed information on reported adverse
events are displayed in Table 4.
DISCUSSION
Varenicline has not been studied in patients with mental
illnesses exclusively, particularly in patients with schizophrenia,
a population with an exceptionally high prevalence of nicotine
addiction. The safety and tolerability of varenicline has been
debated and questioned, especially after initial case reports and
small case series showed an increased risk of neuropsychiatric
adverse effects (23, 24, 50–53) in psychiatric populations.
However, subsequent studies from case reports and case series
to larger clinical trials (9, 15, 19, 31, 33, 37, 42, 43, 45, 46, 53–
59) have demonstrated that the medication is well tolerated
and safe to use to aid schizophrenia patients with smoking
cessation.
Though the therapeutic potential of varenicline has been
questioned in a recent meta-analysis (40), a thorough review
of published studies in recent years provides adequate evidence
that varenicline is an effective aid in smoking cessation in
the schizophrenic population. A systematic review of the
Cochrane database was conducted by (41) to evaluate the
benefits and drawbacks of different treatments for nicotine
dependence in schizophrenia. The authors found that smokers
with schizophrenia who used varenicline were nearly five times
more likely to abstain from smoking at the end of the treatment
when compared to the placebo group. However, these results
were obtained by analyzing a very small sample consisting of
only two trials (19, 33) (2 trials N = 137, RR 4.74, 95%CI 1.34
to 16.71).
Looking at more evidence from published trials such as
Weiner et al. (19) studied varenicline for smoking cessation
in eight patients with schizophrenia. In this RCT, the authors
attempted to test the safety, tolerability, and efficacy of
varenicline. The study determined varenicline to be safe
and well-tolerated by schizophrenic patients (three of the
four participants in the varenicline group were able to
achieve sustained abstinence) and were not associated with
any worsening of negative symptoms or other psychiatric
symptoms as measured using BPRS scales. Overall, the side
effects reported in the varenicline group included nausea,
insomnia, constipation, all of which have been reported as
side effects in the general population as well. Similarly, a
12-week randomized trial by William et al. (33) studied the
efficacy of varenicline for smoking cessation in patients with
stable schizophrenia or schizoaffective disorder. The study
reported that at the end of treatment, 16 out of 84 in the
varenicline group (19.0%) met smoking-cessation criteria vs.
2 out of 43 (4.7%) for the placebo group (P = 0.046). The
study found varenicline to be a promising aid for smoking
cessation, with higher rates of significance than placebo.
Additionally, the study indicated that varenicline was well
tolerated in schizophrenic patients for smoking cessation and
Frontiers in Psychiatry | www.frontiersin.org 6 September 2018 | Volume 9 | Article 428
Ahmed et al. A Meta-Analysis
TABLE 5 | Analysis summary of the parameters studied and their outcome.
Outcome Varenicline N Placebo N Estimate 95% CI Q
Type Effect
Cigarettes/day 133 94 SMD 0.89*** 0.57, 1.22 1.33
Expired carbon monoxide 49 51 SMD 0.50* 0.06, 0.94 0.22
Abstinence 88 47 Log OR 1.81* 0.41, 3.20 0.57
N, number; SMD, standardized mean difference; OR, Odds Ratio; CI, confidence intervals; *p < 0.05; ***p < 0.001.
did not show any evidence of exacerbation of neuropsychiatric
symptoms,
In 2015, a meta-analysis was conducted by Roberts et al. to
assess the efficacy and tolerability of adjunctive pharmacotherapy
for smoking cessation in patients with severe mental illnesses
including schizophrenia, schizoaffective disorder, bipolar
disorder, delusional disorder, and depressive psychoses
(60). The authors analyzed published studies to examine
the various smoking cessation pharmacotherapy modalities
including nicotine replacement therapy (NRT), bupropion,
and varenicline. The meta-analysis of a total of 17 studies
suggested that bupropion and varenicline were more effective
than placebo in a severely mentally ill population. A year later,
another meta-analysis was conducted by Wu et al. (61) to
determine the safety and effectiveness of varenicline in treating
tobacco dependence in patients with severe mental illness,
one of which was schizophrenia. This review analyzed eight
randomized controlled trials in which the researchers compared
varenicline with placebo or an alternative intervention for
smoking cessation or reduction. The primary outcome measures
of interest in the study were smoking cessation, measured by
observing a change in the number of cigarettes smoked per
day and the safety of varenicline smoked per day and the safety
of varenicline, measured by noting the number of adverse
psychiatric events. The study demonstrated that varenicline
was significantly more effective than placebo, increasing the
chance of success fourfold when compared to placebo; also,
the reduction in smoking was greater in people with severe
mental illness (SMI) when compared to the placebo group. The
study defines SMI broadly to include non-organic disorders
with psychotic features, schizophreniform and schizoaffective
disorders, bipolar disorder, or delusional disorder. Although
the study’s results were found in favor of varenicline, the
major limitation of this analysis was its inclusion of small-size
trials, and the follow-up periods in all of the studies were
short.
Kishi et al. (40) conducted a meta-analysis of randomized,
double-blind, placebo-controlled trials (RCTs) to find the effects
of varenicline adjuvant therapy for smoking cessation in
people with schizophrenia. The results of the study suggested
that, varenicline adjuvant therapy is not superior to placebo
for smoking cessation in people with schizophrenia. Further,
the study found that varenicline adjuvant therapy failed to
show its superiority to placebo for positive, negative, and
depressive symptoms. However, the study concluded that
varenicline is well tolerated for smoking cessation in this
population. Because of the many limitations of their meta-
analysis including small-sample-size studies; the authors suggest
further studies to examine varenicline on a larger scale with
larger sample sizes. Nevertheless, the results of this meta-
analysis came as a surprise to the psychiatric community,
especially addiction psychiatrists. As a result of this study,
Evins et al. (62) responded to this meta-analysis with a letter
that highlighted the errors of the meta-analysis and mentioned
that Kishi et al. (40) inappropriately included two trials which
were not smoking cessation trials and that those trials were
conducted on schizophrenic patients who had no intention of
quitting. This caused the investigators to draw the erroneous
conclusion that varenicline is ineffective for smoking cessation.
Additionally, the meta-analysis inappropriately included a RTC
trial by Shim et al. in which varenicline was examined as
a cognitive enhancing agent (57). The meta-analysis also
inappropriately included a relapse prevention trial of smoking
cessation in schizophrenia patients (63). Although it is highly
commendable that Kishi et al. (40) examined the effectiveness
and safety of varenicline, a traditionally understudied topic.
Because of analysis included inappropriate trial studies, the
results of meta-analysis were opposite to numerous evidenced-
based trials. Such error could lead readers to draw the
wrong conclusions; therefore, the results could cause potential
harm and lead to an underuse of this medication in this
population.
Such erroneous findings as discussed above urged scientific
community including authors of the current study to conduct
an updated meta-analysis. Consequently, we did the meta-
analysis using comprehensively defined inclusion and exclusion
criteria. The results of our study show that varenicline is an
effective and safe drug to use for smoking cessation in patients
with schizophrenia. It is well tolerated and an effective aid in
reducing cigarette consumption. The novelty of the current study
is evidenced by results of the study, which were drawn after
modifying and refining our analytic methodology. We expanded
the parameters literature search, added recently published studies
especially after 2015. Further, our study has a few strengths
such as refining our inclusion criteria to target only studies that
elucidated the efficacy and safety of varenicline for smoking
cessation in schizophrenic patients. We did not consider any
relapse prevention studies nor trials that examined the role
of varenicline as a cognition-enhancing drug for smokers and
nonsmokers; such an addition might have contaminated the
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sample and therefore lead to erroneous results. We assessed
the quality of evidence by using the Cochrane tool, which is
the universally accepted and recommended methodology for
analysis of randomized trials. Moreover, compared to previously
published meta-analysis, our electronic search for studies was
carried out on five major databases, PubMed, Scopus, EMBASE,
Web of Science, and Cochrane Library, a reasonably appropriate
large search for performing a systematic review and meta-
analysis.
Our study has suffered from limitations such as the small
number of included participants; thus, our results should be
implemented cautiously in clinical practice. The studies which
we didn’t include in the study are Dutra et al. (42), Pachas et al.
(9), Fatemi et al. (2), Coles et al. (32) due to the lack of common
variables and measures to assess final outcomes and the lack of
relevant data from which we could extract information such as
conference posters or abstracts only. Additionally, we excluded
studies for which there was no control group (Table 1). Another
limitation of our study was the unclear risk of bias regarding the
selection of participants among all included RCTs. We also could
not carry out subgroup meta-analysis or meta-regression due to
the small number of included RCTs.We did not conduct pre- and
post-meta-analysis for studies with no control group, and only
those with a control arm were eligible for inclusion within our
study.
CONCLUSION AND FUTURE
PERSPECTIVES
While the current meta-analysis demonstrates therapeutic
efficacy of varenicline in promoting smoking cessation in
clinically stable schizophrenic patients, however the concussion
is subjected to certain limitations. Because of our well-established
inclusion criteria and because of the relatively few clinical studies
performed on this topic, we analyzed only a small number
of studies. However, larger controlled trials on this topic are
needed to draw firm and evidence based conclusion. Future
clinical studies should consider assessing the impact of the
duration of varenicline treatment, its role in relapse prevention
over extended periods of time, dose dependent responses for
smoking cessation, and consider smoking reduction in addition
to smoking cessation.
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